ArticleHypertension research : official journal of the Japanese Society of Hypertension2021
Long-term outcomes after renal denervation in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea).
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of renal denervation on blood pressure in patients with hypertension: a latest systematic review and meta-analysis of randomized sham-controlled trials.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Pooled it
- Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Pooled it
- Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Trial
- Is Renal Denervation Effective in Treating Resistant Hypertension?Electrolyte & blood pressure : E & BP · 2024Review
- Renal Denervation as a Complementary Treatment Option for Uncontrolled Arterial Hypertension: A Situation Assessment.Journal of clinical medicine · 2023Review
- Catheter-based renal denervation in Chinese patients with chronic kidney disease and uncontrolled hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2023Observational
- A recent advance in Renal denervation to clinical practice.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- 2022 Malaysian Working Group Consensus Statement on Renal Denervation for management of arterial hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Long-term blood pressure lowering effect of renal denervation and its patient preference, salt intake, and stroke in Asia.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Latest hypertension research to inform clinical practice in Asia.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Seven-action approaches for the management of hypertension in Asia - The HOPE Asia network.Journal of clinical hypertension (Greenwich, Conn.) · 2022Review
- A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Perspectives of renal denervation from hypertension to heart failure in Asia.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Patient preference: messages for the wider adoption of renal denervation in the real world.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this work was to investigate the long-term safety and efficacy of renal denervation in Korean patients from the Global SYMPLICITY Registry (GSR). GSR Korea is a substudy of GSR with additional inclusion and exclusion criteria compared to GSR, including inclusion criteria of office systolic blood pressure ≥160 mmHg, or ≥150 mmHg for type 2 diabetes patients, while receiving 3 or more antihypertensive medications without changes for 2 weeks prior to enrollment. Renal denervation was performed using a Symplicity Flex catheter for ablation in the main renal arteries. Changes in office systolic blood pressure and adverse events were collected for up to 36 months of follow-up for 102 patients in GSR Korea. In addition, adverse events and reductions in office systolic blood pressure were analyzed for patients with and without type II diabetes mellitus. Renal denervation led to mean (± standard deviation) reductions in office systolic blood pressure at 12, 24, and 36 months in GSR Korea (-26.7 ± 18.5, -30.1 ± 21.6 mmHg, and -32.5 ± 18.8, respectively). The proportion of patients with a ≥10 mmHg office systolic blood pressure reduction from baseline was 86.3% at 12 months, 86.5% at 24 months, and 89.7% at 36 months. Adverse events at 3 years were rare. In addition, reductions in office systolic blood pressure were similar for patients with vs. without diabetes mellitus (p > 0.05 at all timepoints). Office systolic blood pressure was safely reduced at up to 36 months post-renal denervation in GSR Korea, and adverse events were rare. In addition, patients with and without diabetes had similar office systolic blood pressure reductions.
Indexed as
Identifiers
34145423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.